![]()
03.06.20132002
Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF).
![]()
31.05.20132173
To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).
![]()
30.05.20132120
The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors (coxibs) and traditional non-steroidal anti-inflammatory drugs (tNSAIDs), are not well characterised, particularly in patients at increased risk of vascular disease.
![]()
29.05.20132068
Patients taking aspirin or warfarin (Coumadin) for prevention after a stroke don't need to stop the drug for dental procedures and probably can stay on it for most other minor medical procedures, the American Academy of Neurology recommended.
![]()
28.05.20132009
Rivaroxaban (Xarelto, Bayer ) has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) following an acute coronary syndrome (ACS).
![]()
27.05.20132178
What is the predictive value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE])?
![]()
24.05.20131819
The risks of sports participation for implantable cardioverter-defibrillator (ICD) patients are unknown.
